Is bioidentical hormone therapy safer than conventional HRT?

No large randomized trial has shown that bioidentical hormones are safer or more effective than conventional hormone therapy. Health Canada-approved products containing bioidentical estradiol and progesterone (such as Prometrium and Estrogel) have been studied in clinical trials and carry the same regulatory scrutiny as any prescription drug. Compounded BHRT preparations have not undergone that review, so their safety profile is less certain — not better established.

What is the difference between compounded BHRT and approved bioidentical hormones?

Health Canada-approved bioidentical products (e.g., estradiol patches, oral micronized progesterone) are manufactured to standardized doses, tested for purity and potency, and reviewed for safety before sale. Compounded BHRT is mixed by a pharmacy to a custom dose and is not subject to federal drug approval; quality can vary batch to batch. Both categories use the same bioidentical molecules, but only the approved products have a documented evidence base from clinical trials.

Is BHRT covered by provincial drug plans in Canada?

Health Canada-approved bioidentical products are listed on most provincial formularies for eligible indications — for example, Ontario's ODB program covers Prometrium and several estradiol formulations for postmenopausal women meeting clinical criteria. Compounded BHRT is generally not covered by provincial plans and is paid out-of-pocket; costs typically range from $50 to $200 or more per month depending on the formulation. Private insurance coverage for compounded preparations varies widely by plan.

Can saliva testing accurately guide BHRT dosing?

No. Saliva hormone levels do not reliably reflect blood hormone concentrations and have not been shown to correlate with menopause symptom severity. The Endocrine Society and Mayo Clinic both advise against using saliva testing to guide hormone therapy decisions. Serum (blood) testing of estradiol, FSH, and testosterone is the validated approach when laboratory measurement is clinically indicated.

Does bioidentical progesterone carry a lower breast cancer risk than synthetic progestins?

Some observational studies — including data from the French E3N cohort — suggest that micronized progesterone may be associated with a lower breast cancer risk than synthetic progestins such as medroxyprogesterone acetate (MPA). However, no powered randomized controlled trial has confirmed this, and the Menopause Society notes the evidence is not yet definitive. Canadian guidelines from the SOGC acknowledge the biological plausibility but stop short of recommending micronized progesterone solely on the basis of breast cancer risk reduction.

Bioidentical hormone replacement therapy — Glossary

What it is

Bioidentical hormone replacement therapy (BHRT) is a form of hormone therapy in which the active hormones are chemically identical in molecular structure to those produced by the human body — most commonly estradiol, progesterone, and testosterone — and is used primarily to manage symptoms of menopause, perimenopause, and andropause. The term "bioidentical" describes the molecular match to endogenous hormones, not the source; most bioidentical hormones are derived from plant sterols (soy or wild yam) that are then chemically converted in a laboratory. BHRT is sometimes called "natural hormone therapy," though that label is misleading: the manufacturing process is industrial regardless of the plant origin.

In Canada, some Health Canada-approved prescription products — including estradiol patches, gels, and oral micronized progesterone (sold as Prometrium) — contain bioidentical hormones and carry the same regulatory oversight as any other drug. A separate, and more contested, category consists of custom-compounded BHRT preparations mixed by compounding pharmacies to individualized doses; these are not reviewed or approved by Health Canada and are not subject to the same quality-control standards as commercially manufactured drugs.

Roughly 1.5 million Canadian women are estimated to be in menopause at any given time, and menopause-related symptoms drive the majority of BHRT prescriptions. Awareness of the distinction between regulated and unregulated BHRT products is essential for informed decision-making.

Causes and mechanism

BHRT is not a disease treatment but a replacement strategy: it compensates for the decline in sex hormones that occurs naturally with age or as a result of surgical menopause, premature ovarian insufficiency (POI), or hypogonadism. Estradiol (the primary estrogen produced by the ovaries) falls sharply at menopause; progesterone drops in parallel; testosterone declines more gradually across the perimenopausal years. BHRT aims to restore circulating levels of these hormones to ranges associated with symptom relief.

Because the molecules are structurally identical to endogenous hormones, they bind the same receptors as the body's own hormones — estrogen receptors (ERα and ERβ), progesterone receptors, and androgen receptors — producing the same downstream signalling. This is the theoretical basis for the claim that bioidentical hormones are better tolerated than synthetic analogues, though that claim has not been confirmed in head-to-head randomized trials.

Symptoms and diagnosis

BHRT is considered when patients present with symptoms attributable to sex-hormone deficiency:

Vasomotor symptoms: hot flashes, night sweats
Genitourinary syndrome of menopause (GSM): vaginal dryness, dyspareunia, recurrent UTIs
Sleep disruption and mood changes
Reduced libido
Bone density loss (in the context of osteoporosis prevention)

Diagnosis is clinical in most cases. Serum hormone levels (FSH, estradiol, total and free testosterone) can support the picture but are not required to initiate therapy in symptomatic perimenopausal or postmenopausal women. Saliva hormone testing, often marketed alongside compounded BHRT, is not validated for this purpose: saliva levels do not reliably reflect serum levels or symptom burden, a point noted by both Mayo Clinic and the Endocrine Society.

Product type	Regulatory status in Canada	Quality oversight	Customizable dose
Health Canada-approved BHRT (e.g., Estrace, Prometrium, estradiol patch)	Approved	Full Health Canada review	No — fixed doses
Compounded BHRT (pharmacy-mixed)	Not approved	No federal review; provincial pharmacy regulation only	Yes
Synthetic HRT (e.g., conjugated equine estrogens, medroxyprogesterone acetate)	Approved	Full Health Canada review	No — fixed doses

Treatment options

Approved bioidentical products available in Canada include oral micronized progesterone (Prometrium 100 mg, 200 mg), estradiol patches (Estradot, Climara), estradiol gel (Estrogel), and vaginal estradiol preparations. These are prescribed by family physicians, gynecologists, and menopause specialists and are covered, at least partially, by most provincial drug benefit plans for eligible indications.

Compounded BHRT — creams, troches, sublingual drops, pellets — is available through compounding pharmacies across Canada. Prescribers in primary care, naturopathic medicine, and some menopause clinics offer these formulations. Because compounded products are not Health Canada-approved, batch-to-batch potency can vary, and long-term safety data specific to compounded preparations are absent.

Testosterone for women (low-dose, off-label) is increasingly prescribed for hypoactive sexual desire disorder; no female-specific testosterone product is currently approved in Canada, so compounded or off-label male formulations are used at fractions of the male dose.

Canadian patients can access BHRT through in-person menopause specialists, family physicians, and virtual care platforms (including Felix, Cleo, Maple, Phoenix, and others) — though prescribing scope and formulary access vary by province.

When to see a clinician in Canada

Seek assessment if vasomotor or genitourinary symptoms are affecting sleep, work, or quality of life, or if you have risk factors for osteoporosis or cardiovascular disease that a hormone therapy decision should account for. The Society of Obstetricians and Gynaecologists of Canada (SOGC) recommends that menopause management be individualized, weighing each patient's symptom burden, cardiovascular history, breast cancer risk, and personal preferences. For most healthy women under 60 or within 10 years of menopause onset, the benefit-risk balance of hormone therapy is generally favourable — a position consistent with the 2023 Menopause Society (formerly NAMS) position statement.

If you are considering compounded BHRT specifically, ask your prescriber to explain why a Health Canada-approved bioidentical product would not meet your needs before proceeding with an unregulated formulation.

Limitations and open questions

Research is still emerging on several important questions. No large randomized controlled trial has directly compared compounded BHRT to approved hormone therapy products on hard clinical endpoints (fracture, cardiovascular events, breast cancer incidence). The safety profile assumed for compounded preparations is largely extrapolated from trials of approved bioidentical drugs — an assumption that may not hold given manufacturing variability.

Health Canada has not issued specific guidance on compounded BHRT beyond general compounding pharmacy regulations, leaving a regulatory gap that provincial colleges of pharmacy partially fill. The long-term cardiovascular and breast cancer risk of low-dose testosterone in women remains under-studied; the Endocrine Society acknowledges the evidence base is insufficient for definitive safety conclusions. Whether bioidentical progesterone carries a lower breast cancer risk than synthetic progestins (medroxyprogesterone acetate) is biologically plausible and suggested by some observational data, but has not been confirmed in a powered randomized trial. Patients and clinicians should weigh these uncertainties explicitly rather than assuming "natural" equals "safe."

Bioidentical hormone replacement therapy